Relationship between dynamic changes of Epstein-Barr virus and efficacy of lymphoma
10.3760/cma.j.issn.1009-9921.2018.06.004
- VernacularTitle:EB病毒动态变化与淋巴瘤疗效的关系
- Author:
Yingxue YANG
1
,
2
;
Kaiyang DING
;
Maogui HU
Author Information
1. 230032 合肥,安徽医科大学研究生院
2. 230001 合肥,安徽医科大学附属省立医院血液科
- Keywords:
Herpesvirus 4;
human;
Lymphoma;
Lactate dehydrogenases;
Lymph nodes
- From:
Journal of Leukemia & Lymphoma
2018;27(6):336-339
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the relationship between the dynamic changes of Epstein-Barr virus (EBV) and the clinical efficacy of lymphoma. Methods The retrospective study was performed on 51 lymphoma patients with EBV-positive in Anhui Provincial Cancer Hospital from September 2015 to August 2017. The treatment effect of lymphoma was evaluated by the changes of EBV DNA, lactic dehydrogenase (LDH) and lymph nodes. Results Among the 51 lymphoma patients, EBV DNA elevated in 18 patients when the LDH was elevated, 23 cases presented with EBV DNA decrease and the LDH also decreased. EBV DNA decreased in 2 patients when the LDH was elevated. Eight patients were elevated when LDH was reduced. The quantification of EBV DNA and LDH had high consistency (κ = 0.609, P= 0.000). Among the 51 lymphoma patients, 20 patients with elevated EBV DNA were elevated with lymph nodeen largement, the lymph nodes in 22 cases with EBV DNA decrease were also decreased. EBV DNA decreased in 3 patients when the lymph nodes were enlarged. Six patients were elevated when lymph nodes were reduced. The quantification of EBV and lymph nodes had high consistency (κ = 0.648, P= 0.000). Patients with elevated EBV DNA during the course of treatment showed an increase in the mean value of LDH, and the patients with reduced EBV DNA during treatment also had lower average LDH. LDH levels were positively correlated with EBV DNA in patients with EBV-positive lymphoma (r= 0.627, P= 0.000). Conclusion Dynamic detection of EBV DNA and LDH can be used as the evaluation index of therapeutic effect and follow-up in patients with EBV-positive lymphoma.
